Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burden of bleeding related episodes in patients with immune thrombocytopenic purpura despite treatment with Eltrombopag or Romiplostim which aims to prevent these episodes: a real world, retrospective study

Trial Profile

Burden of bleeding related episodes in patients with immune thrombocytopenic purpura despite treatment with Eltrombopag or Romiplostim which aims to prevent these episodes: a real world, retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 New trial record
    • 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top